Cannabis In Minnesota, 2019 (Part 2): State Licensed Medical Producers In The Red.
Minnesota’s medical cannabis companies reported a combined $2.4 million loss in 2018, highlighting ongoing challenges within the state’s regulated program. Limited patient eligibility and strict program requirements continue to restrict access to medical cannabis in Minnesota, while demand for alternative hemp-derived CBD products remains steady.
Minnesota Medical Cannabis Market Challenges and Industry Outlook
The current framework limits patient eligibility and access, leaving many residents unable to participate in the state’s medical cannabis program. As a result, access to cannabis-derived products remains restricted despite growing demand.
Stigma Hemp provides an alternative option for consumers seeking hemp-derived CBD products, including formulations made with full-spectrum, CBD-rich CO₂ extracts. These products operate within the federal hemp framework established by the 2018 Farm Bill.
